# SB208 for the Treatment of Tinea Pedis

> **NCT02860052** · PHASE2 · COMPLETED · sponsor: **Novan, Inc.** · enrollment: 222 (actual)

## Conditions studied

- Tinea Pedis

## Interventions

- **DRUG:** SB208 2%
- **DRUG:** SB208 4%
- **DRUG:** SB208 16%
- **DRUG:** Vehicle Gel

## Key facts

- **NCT ID:** NCT02860052
- **Lead sponsor:** Novan, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-19
- **Primary completion:** 2017-01
- **Final completion:** 2017-02-01
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02860052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02860052, "SB208 for the Treatment of Tinea Pedis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02860052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*